Clinical Relevance of Minimal Residual Cancer in Patients with Solid Malignancies


With the advent of new therapeutic modalities, the treatment options for oncologists can vary greatly depending upon the aggressiveness of the patient's cancer. Patients may receive no therapy, adjuvant therapy, aggressive adjuvant therapy (taxane based), monoclonal antibody therapy (e.g. Herceptin) or bone marrow transplantation. It is now mandatory to… (More)
DOI: 10.1023/A:1006264420822


1 Figure or Table